Bodhi: composition, regulatory status, and the evidence gap

A quiet reading corner with a linen chair, open book, and warm lamplight

Bodhi is a named combination of semax, selank, BPC-157, and KPV. Two components are approved as medicines in Russia but not in the United States, and two come from tissue and inflammatory signalling research. No study of the combination was identified.

Composition

  • semax
  • selank
  • bpc-157
  • kpv

Overview

This grouping combines two nootropic-category peptides with two peptides from repair and inflammatory research. The most important regulatory fact is that semax and selank have marketing approval in Russia and none in the United States, which means the research literature that exists is real but was not the basis of an FDA review. That distinction is often lost in marketing, and it matters for how much confidence a reader should place in it.

Why these are grouped

The rationale offered is that cognition and mood might be discussed alongside gut and inflammatory signalling, on the reasoning that these systems interact. Systems interacting in biology is not the same as four substances producing a combined benefit. No published work tested this grouping.

What each ingredient contributes

semax

A peptide with Russian marketing approval and a research literature published largely in Russian-language journals. It is not FDA-approved.

selank

A peptide studied in Russia in the anxiety context, also not FDA-approved and with limited Western replication.

bpc-157

Studied in animal models of tissue and gut signalling, with no adequate human trial base.

kpv

A tripeptide fragment studied in preclinical models of inflammatory signalling, with minimal human data.

Combination evidence

  • No published or registered study of the Bodhi combination was identified.
  • No safety data describe these four substances used together.
  • No evidence supports a cognitive or mood claim for the combination.

Semax and selank have real published research, largely conducted in Russia and published in venues with limited Western replication. That is not the same as no evidence, and it is also not the same as FDA-grade evidence. BPC-157 and KPV are preclinical. None of this describes the combination.

Preclinical rationale

  • Semax and selank are studied for effects on neuropeptide and neurotransmitter signalling.
  • BPC-157 appears in animal models of gut and tissue signalling.
  • KPV appears in preclinical models of inflammatory pathways.

What is not established

  • Any cognitive or mood benefit in healthy adults from the combination.
  • Whether Russian trial findings replicate under contemporary Western methodology.
  • Safety of the combination at any duration.
  • Interaction with psychiatric medicines.

Questions to discuss with a physician

  • Is any of this appropriate given my mental health history and current medicines?
  • What does the Russian research actually show, and how much weight should it carry?
  • What established options exist for what I am describing?
  • How would we tell whether it is working rather than just feeling different?
  • What would make you stop?

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-15.